Shahid Ahmad

New Funding Available: HealthBound II - Improve Patient Wait Times in an Outpatient Clinic at St. Michael's

The Biomedical Zone has opened up applications for HealthBound II, aimed at finding a solution to improve patient wait times in an outpatient clinic at St. Michael's.

  • The winning company will receive:
  • A cash prize of $5000
  • Residency in the Biomedical Zone
  • A subsidized pilot opportunity at St. Michael's 
  • Mentorship and immersion from clinicians, hospital administrators, and IT

Qvella Raises US$20M in Series B Financing to Fund Clinical Trials, On-Going Research, Team Expansion, and Manufacturing Buildup

December 4, 2017 – Qvella, a leading molecular diagnostics company closed US$20 million in Series B financing. The funding round was co-led by Qvella’s existing investor syndicate – including RA Capital, Whitecap Venture Partners, Hatteras Ventures, and Sands Capital – and new strategic investor bioMérieux, a world leader in the field of in vitro diagnostics. The proceeds will be used to fund clinical trials, to support on-going research and development, and to facilitate team expansion and manufacturing scale-up.

Thornhill Research & Rostrum Medical Announce Technology Development Agreement

TORONTO, ON  Thornhill and Rostrum celebrate the finalization of a Technology Development Agreement which includes the licensing of certain Thornhill IP and an investment by Rostrum into Thornhill. This agreement is aimed to further Rostrum’s development of its Pulmonary Health Monitoring during ventilation, in ICU, OR and ER applications while supporting Thornhill’s commercialization efforts of their own innovative products.

KalGene Pharmaceuticals Closes Financing to Support the Clinical Development of its Alzheimer's Therapeutic

TORONTO, ON  KalGene Pharmaceuticals announced the closing of a Series A financing to support the advancement of its lead Alzheimer's therapeutic program. The syndicated investment was led by Lumira Capital and included participation from Anges Québec, Anges Québec Capital, Accel-Rx Health Sciences Accelerator and a number of Canadian family offices. In addition to the equity financing the company has also received significant financial support from leading Foundations focused on neurodegenerative diseases. Proceeds from these combined funding sources will support the development of KalGene's lead Alzheimer's therapeutic candidate.

Ontario Announces Dr. Molly Shoichet As First Chief Scientist

Ontario has appointed Dr. Molly Shoichet as the province's first Chief Scientist with a mandate to advance science and innovation in Ontario. The new Office of the Chief Scientist will report to Reza Moridi, Minister of Research, Innovation and Science.

Dr. Shoichet is a professor at the University of Toronto, a member of the Order of Ontario, and founder of Hammock Therapeutics, an OBIO CAAP company. 

CCAB Welcomes Mr. Robert Verhagen as New CEO

The Centre for the Commercialization of Antibodies and Biologics (CCAB) Board of Directors is pleased to announce the appointment of Mr. Robert Verhagen as the organization’s new Chief Executive Officer, effective November 1, 2017.

As CCAB’s new CEO, Mr. Verhagen will provide his strategic direction to position CCAB as a leader in the commercialization of academic discoveries in the biologics field and in the advancement of this biotech sector in Canada.

CAAP Company: Conavi Medical, China Grand Pharmaceutical & Healthcare Enter Distribution Agreement for Minimally Invasive Imaging Technologies in China

2015 CAAP Company Conavi Medical Inc., a privately-held company developing image guidance technologies for minimally invasive procedures announced that it has entered into an agreement with an affiliate of China Grand Pharmaceutical and Healthcare Holdings Limited (CG Healthcare) to serve as the exclusive distributor of its ForesightTM Intracardiac Echocardiography (ICE) and NovasightTM Hybrid Intravascular Imaging systems in China, Hong Kong, Taiwan and Macau.

Canadian Technology Accelerator (CTA) Initiative Accepting Applications - Spring 2018 Cohorts (February–June 2018)

Application Deadline January 10, 2018 - Apply Here

The Canadian Technology Accelerator Initiative (CTA) helps high-potential, high-growth Canadian technology SMEs seeking to expand to the U.S through a 5 month program of workshops, events, mentorship and business introductions.

Baylis Devices & Expanded Training Program: European Doctors Learn to Access the Heart from Any Approach

Baylis Medical Company Inc. has launched a hands-on workshop in Europe that will train cardiologists on innovative tools that enable access to the heart from any approach. This includes a growing number of procedures that require physicians to use major veins that feed into the heart from above.